MX2019008656A - Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire. - Google Patents

Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire.

Info

Publication number
MX2019008656A
MX2019008656A MX2019008656A MX2019008656A MX2019008656A MX 2019008656 A MX2019008656 A MX 2019008656A MX 2019008656 A MX2019008656 A MX 2019008656A MX 2019008656 A MX2019008656 A MX 2019008656A MX 2019008656 A MX2019008656 A MX 2019008656A
Authority
MX
Mexico
Prior art keywords
air pollutants
composition
nasal
silicon dioxide
risks
Prior art date
Application number
MX2019008656A
Other languages
English (en)
Inventor
Mattern Claudia
Original Assignee
M et P Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M et P Pharma AG filed Critical M et P Pharma AG
Publication of MX2019008656A publication Critical patent/MX2019008656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para reducir los riesgos de la exposición a contaminantes del aire, que comprenden administrar por vía nasal a un sujeto que lo necesita una composición que contrarresta los efectos de uno o más contaminantes del aire, en donde la composición está adaptada para la administración nasal. En algunas formas de realización, la composición comprende un agente que se fija a uno o más contaminantes del aire, en donde el agente comprende uno o ambos de dióxido de silicio no poroso y dióxido de silicio poroso y/o la composición proporciona una barrera física entre uno o más contaminantes del aire y las superficies nasales internas. En la presente también se describen composiciones nasales que comprenden un agente que comprende uno o ambos de dióxido de silicio no poroso y dióxido de silicio poroso, un vehículo lipófilo o parcialmente lipófilo, y un tensioactivo, en donde la composición está adaptada para la administración nasal. En la presente también se describen métodos para fabricar y utilizar composiciones farmacéuticas nasales.
MX2019008656A 2017-01-20 2018-01-19 Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire. MX2019008656A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448556P 2017-01-20 2017-01-20
US201762517369P 2017-06-09 2017-06-09
PCT/IB2018/050349 WO2018134783A1 (en) 2017-01-20 2018-01-19 Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants

Publications (1)

Publication Number Publication Date
MX2019008656A true MX2019008656A (es) 2019-11-21

Family

ID=61094560

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008656A MX2019008656A (es) 2017-01-20 2018-01-19 Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a los contaminantes del aire.
MX2022006529A MX2022006529A (es) 2017-01-20 2019-07-19 Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006529A MX2022006529A (es) 2017-01-20 2019-07-19 Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire.

Country Status (11)

Country Link
US (1) US10729646B2 (es)
EP (1) EP3570848B1 (es)
KR (1) KR20190109452A (es)
CN (1) CN110461340A (es)
CA (1) CA3050361A1 (es)
ES (1) ES2948282T3 (es)
HU (1) HUE063346T2 (es)
MX (2) MX2019008656A (es)
RU (1) RU2019123307A (es)
SG (1) SG11201906616VA (es)
WO (1) WO2018134783A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026041A1 (en) 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
KR20200116103A (ko) 2018-01-11 2020-10-08 엠 이티 피 파마 아게 탈수초성 질환의 치료
KR20210028409A (ko) 2019-09-04 2021-03-12 엘지디스플레이 주식회사 유기 화합물, 이를 포함하는 유기발광다이오드 및 유기발광장치
US20210275989A1 (en) * 2020-03-05 2021-09-09 Performance Labs PTE. LTD. Functional materials and devices for reducing toxic pollutants
IL302986A (en) * 2020-11-19 2023-07-01 Acousia Therapeutics Gmbh A non-aqueous gel preparation
CN114653172B (zh) * 2022-03-15 2023-11-14 江苏理工学院 一种协同脱除VOCs和Hg0的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546882A (en) 1983-02-07 1985-10-15 American Can Company Package having oil-containing product
US5002597A (en) * 1989-04-03 1991-03-26 Invent Ag Aerodynamic filter
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
EP1933811A2 (en) 2005-09-30 2008-06-25 Alza Corporation Banded controlled release nanoparticle active agent formulation dosage forms and methods
PT2068825E (pt) * 2006-10-04 2011-02-11 M & P Patent Ag Sistema de administração de libertação controlada para aplicação nasal de neurotransmissores
US8258137B2 (en) 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
EP2480210A4 (en) 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
JP2010083834A (ja) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd アレルゲン不活性化剤、及びそれを含有する化粧料。
US8778401B2 (en) 2008-10-28 2014-07-15 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
US20130040922A1 (en) * 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP6562630B2 (ja) * 2011-05-13 2019-08-21 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用
KR20210135003A (ko) * 2011-05-15 2021-11-11 에이세러스 바이오파마 인크. 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도
BR112014021218A2 (pt) * 2012-02-27 2020-10-27 Bayer New Zealand Limited composições de liberação controlada e seus métodos de uso
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US20150290217A1 (en) 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
EP3193836A1 (en) 2014-09-15 2017-07-26 PharmaSol GmbH Active-loaded particulate materials for topical administration
JP2018522050A (ja) * 2015-08-04 2018-08-09 インキューファーム グループ エスディーエヌ ビーエイチディー 経鼻組成物
EP3347124A1 (en) * 2015-09-09 2018-07-18 King Abdullah University Of Science And Technology Functionalized sio2 microspheres for extracting oil from produced water
CA3026041A1 (en) 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient

Also Published As

Publication number Publication date
WO2018134783A1 (en) 2018-07-26
ES2948282T3 (es) 2023-09-07
CN110461340A (zh) 2019-11-15
KR20190109452A (ko) 2019-09-25
EP3570848C0 (en) 2023-06-07
EP3570848A1 (en) 2019-11-27
HUE063346T2 (hu) 2024-01-28
MX2022006529A (es) 2022-07-11
SG11201906616VA (en) 2019-08-27
RU2019123307A3 (es) 2021-05-24
CA3050361A1 (en) 2018-07-26
US10729646B2 (en) 2020-08-04
US20180296472A1 (en) 2018-10-18
RU2019123307A (ru) 2021-02-20
EP3570848B1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
MX2022006529A (es) Composiciones farmaceuticas nasales para reducir los riesgos de la exposicion a contaminantes del aire.
MX2018014906A (es) Composiciones farmaceuticas nasales con un excipiente poroso.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
ATE496617T1 (de) Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern
MX2015014890A (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
RS52199B (en) PHARMACEUTICAL COMPOSITIONS OF THE NEUROACTIVE STEROID AND THEIR USE
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2011141685A3 (fr) Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
CO7101247A2 (es) Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
BR112019001134A2 (pt) uso de lactama e composição farmacêutica
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
MX2016005720A (es) Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.